Voyager Therapeutics, Inc. VYGR

VYGR Company Overview

Voyager Therapeutics, Inc. is a U.S.-based biotechnology company focused on the development of genetic medicines for neurological diseases. The company operates within the biotechnology and gene therapy industries, with a strategic emphasis on adeno-associated virus (AAV)-based delivery technologies and RNA-targeted therapeutics for central nervous system (CNS) disorders. Voyager’s core business centers on discovering and developing vectorized therapies capable of delivering genetic payloads across the blood-brain barrier, an area considered a major challenge in neurological drug development.

The company’s primary revenue sources have historically included collaboration agreements, licensing arrangements, and research partnerships rather than commercialized product sales. Voyager has established partnerships with major pharmaceutical companies to advance programs in diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Friedreich’s ataxia. A distinguishing aspect of the company’s positioning is its proprietary capsid discovery platform, which is designed to improve tissue targeting and delivery efficiency for gene therapies. Founded in 2013, Voyager evolved from an early-stage CNS gene therapy developer into a platform-focused biotechnology company after restructuring portions of its internal pipeline and prioritizing strategic collaborations and vector technology development.